Introduction: Cigarette smoking is one of the largest causes of preventable death worldwide. This study aimed to identify susceptibility loci for age at smoking initiation (ASI) by performing an exome-wide association analysis. Methods: A total of 2510 smokers of either African-American (AA) or European-American (EA) origin were genotyped and analyzed at both the single nucleotide polymorphism (SNP) and gene levels. After removal of those SNPs with a minor allele frequency (<0.01), 48 091 and 34 933 SNPs for AAs and EAs, respectively, were used to conduct a SNP-based association analysis. Gene-based analyses were then performed for all SNPs examined within each gene. Further, we estimated the proportion of variance explained by all common SNPs included in the analysis.
Introduction
Tobacco is the most widely used addictive substance and the leading preventable cause of diseases, disability, and deaths throughout the world. Tobacco smoking has been associated with a higher risk of several cancers and cardiovascular and respiratory diseases. 1 According to the recent World Health Organization survey, more than 1.3 billion persons in the world smoke, and smoking-related diseases are responsible for approximately 6 million deaths each year worldwide, a number predicted to increase to 8.3 million by 2030. 2 Smoking behaviors, including age at smoking initiation (ASI), smoking dependence (SD), and smoking cessation (SC), are all complex phenotypes determined by both genetic and environmental factors as well as their interactions. 3 Twin, family, and adoption studies have indicated that genetic factors play a significant role in smoking initiation (SI), dependence, and cessation. [3] [4] [5] Previous studies have estimated the heritability of different smoking phenotypes with a range of 21% to 84%. [6] [7] [8] To identify susceptibility loci for each smoking phenotype, numerous studies have been conducted, with approaches including genome-wide linkage scans, 9 candidate gene-based association analyses, and the genome-wide association study (GWAS). Of those loci identified by various approaches, especially with GWAS, the most robust findings are for the variants in the CHRNA5/CHRNA3/CHRNB4 cluster on chromosome 15q25.1, [10] [11] [12] such as rs16969968 and rs1051730, which are significantly associated with the number of cigarettes smoked per day (CPD) and the Fagerström Test for Nicotine Dependence (FTND) score. The evidence supporting the involvement of nAChRs in the etiology of ND is indisputable, in part, because of their essential role in mediating the rewarding effects of nicotine. 13 Further, CHRNA6/CHRNB3 on chromosome 8p11 12 and CYP2A6 on chromosome 19q13 12 are consistently associated with CPD at the genome-wide significance level. 12 Previous studies have implicated CHRNA6/CHRNB3 subunits in nicotine-induced dopamine release, 14 and variants in CYP2A6 reduce the enzymatic activity of CYP2A6. 15 For other smoking behaviors, GWAS revealed that BDNF on chromosome 11p13 and RGS17 on chromosome 6q25 are significantly associated with SI 16, 17 and DBH on chromosome 9q34 and PARD3 on chromosome 10p11 with SC in multiracial populations. 16, 18 Of these important SNPs, less than 5% of the variance can be explained by those variants for each phenotype of interest. To explore the missing heritability, one common approach is to detect multiple alleles in the same gene region that affect the same trait. Gene-based association testing can improve statistical power in the presence of allelic heterogeneity by combining single variants from GWAS into a gene-based score. 19 In this study, we employed the "Versatile Gene-Based Association Study 2" (VEGAS2) approach 20 to assign variants to genes and calculate gene-based p values based on computer simulation.
The majority of reported GWAS for smoking phenotypes were conducted in the people of European ancestry. 21 However, 22 AfricanAmericans generally initiate smoking later and smoke fewer cigarettes per day, but they are less likely to be able to quit smoking and have a higher risk of smoking-related lung cancer than EuropeanAmericans. Therefore, to conduct GWAS for smoking behavior, especially for ASI in African populations, is greatly needed.
Nearly 90% of adult smokers begin their smoking before or at the age of 18, and, at present, one-fourth of young adults are smokers. 23 Although the majority of smokers try to quit, smoking cessation cannot be achieved easily, primarily because of the addictive physiological and psychological properties of nicotine. According to a cross-sectional study, early SI is associated with a higher probability of becoming a heavier smoker and a lower rate of smoking cessation success. 24 More importantly, in current smokers, early SI is independently associated with a higher lung cancer risk after adjusting for CPD. 39 Because of the high cost of obtaining sufficient statistical power, whole-genome sequencing analysis was not conducted in this study. To reveal the molecular mechanism underling each smoking phenotype, we used high-throughput approaches such as exome-based association study to identify genetic variants that contribute to ASI and other smoking-related phenotypes.
Material and Methods

Subjects and Demographic Characteristics
A total of 2510 smokers selected from the Mid-South Tobacco CaseControl (MSTCC) study were included in this study. A detailed description of the inclusion and exclusion criteria used for the recruitment of the MSTCC sample has been published previously. 26 Among them, individuals who exhibited other substance dependence or abuse (such as marijuana, cocaine, morphine) except for alcohol use or abuse (<10%) were excluded. All research protocols were approved by each participating Institutional Review Board, and written informed consent was obtained from all participants.
This sample set consisted of 1654 unrelated AA smokers (857 males and 797 females) and 856 unrelated EA smokers (422 males and 434 females). All participants had smoked at least 100 cigarettes in their lifetimes. 26 Detailed characteristics of the MSTCC AA and EA samples are presented in Table 1 .
Phenotype of Interest
Almost all answers were self-reported, with the structured questionnaire being administered by a specially trained clinical study researcher. Questionnaires used to assess smoking-related behaviors included the FTND, 27 the CPD, SI (in ever vs. never smokers), ASI, and smoking cessation (former vs. current smokers). For the objectives of this study, only ASI was analyzed. The question used to measure ASI was "How old were you when you started smoking regularly?" This phenotype was treated as a continuous variable among ever smokers.
Genotyping and Quality Control
Genomic DNA was extracted from EDTA-treated peripheral venous blood of each subject using the Qiagen DNA purification kit. All DNA samples were treated with RNase A to remove potential contaminating RNA, and DNA quality and the concentration of each sample was determined by the A260/A280 absorbance ratio. All samples were genotyped using the Illumina Infinium Human Exome BeadChip (Illumina, Inc., San Diego, CA, USA) according to the manufacturer's protocol. This chip aims to detect the association of rare variants with larger effect size and was developed from functional exonic variants (> 90%) and disease-associated tag markers found at least three times in more than two datasets from the whole-exome sequencing of more than 12 000 individuals (www. illumina.com).
After genotyping, we performed the following quality control analyses on all genotyped SNPs. First, among 242 901 genotyped variants, we excluded all insertions and deletions to ensure that all base pair positions were unique and referred to the same variant. Second, any SNP with a call rate of <95% was excluded. Third, we removed those SNPs that were not in Hardy-Weinberg equilibrium at a p value of < 1.0 × 10 −6 . Finally, we used a 1% minor allele frequency (MAF) as a threshold to define rare and common variants, and any SNP with an MAF of <1% was excluded from the analysis.
Strict and rigorous quality control was implemented in both sample selection and population substructure assessments. The samples with incomplete phenotypic information were removed. Meanwhile, to evaluate the population structure and identify potential outliers, we performed principal components analysis (PCA) using EIGENSTRAT. 28 All individual SNP-and gene-based association analyses were performed for the AA and EA samples separately. After the quality control steps, a final total of 48 095 SNPs in the 1654 AA sample and 34 992 SNPs in the 856 EA sample were retained for the association analysis.
Association Analysis
For individual SNP-based association analysis, we used the PLINK (v. 1.07) 29 to perform multiple linear regression under the additive genetic model with sex, age, and the first three principle components as covariates in the AA and EA samples separately. Considering the type of chip used in the study and the number of SNPs included in each chip, Bonferroni correction rather than the commonly adapted genome-wide significant p value of 10 -8 was adopted for this study. To predict the function of the intronic SNPs, the online bioinformatic tools SNPnexus, 30 SIFT, 31 and Polyphen 32 were used.
Gene-based Analysis Using VEGAS2
The VEGAS2 approach was used for the gene-based association test. 20 This tool summarizes association signals from all the SNPs within each gene, considering linkage disequilibrium (LD) between markers based on HapMap data and calculated as the sum of all χ 2 -converted SNP p values within the gene that were generating by PLINK. The significance of each gene was determined with the Bonferroni-corrected p value for the number of genes examined.
SNP Heritability
The heritability of the joint effect of all SNPs (ie, SNP heritability or h 2 SNP ) was estimated using the restricted maximum likelihood analysis implemented in the genome-wide complex trait analysis package (GCTA). 33 After calculation of the genetic relation matrix (GRM), h 2 SNP was estimated using a linear mixed model in which the measure of genetic similarity was included as a random effect to predict the phenotype of interest.
Results
As shown in Table 1 , this study included 1654 AA and 856 EA smokers. For these smokers, the CPD (mean ± SD) was 26.4 ± 6.4 and 27.8 ± 7.0, and the average ASI (mean ± SD) was 18.4 ± 2.7 and 17.7 ± 3.6 years, for the AA and EA smokers, respectively. To define the relation between CPD and ASI, a correlation test was conducted, which revealed a negative correlation in both AAs (p = −0.047) and EAs (p = −0.051).
SNP-based Association Analysis
As stated earlier, after various QC steps, 48 091 and 34 933 autosomal SNPs remained for genome-wide association analysis in the AA and EA samples, respectively. We observed no evidence of systematic genomic inflation for the test statistic (ie, λ = 1.000) for all genotyped SNPs secondary to population stratification.
Of those SNPs identified by EWAS, one remained statistically significant after Bonferroni correction in the AA sample and another in the EA sample. For the AA sample, the strongest associated signal was achieved for rs17849904 in the pitrilysin metallopeptidase 1 gene on chromosome 10p15 (PITRM1; p = 9.02 × 10 −7
; MAF = 0.012), a gene involved in modulating both metalloendopeptidase and enzyme activator activity that has been associated with Alzheimer's disease. 34 In the EA sample, the most significant association was observed for rs34722354 (p = 9.74 × 10 −7 ; MAF = 0.02), located in the 5′-untranslated region (UTR) of DDR2 on chromosome 1q23. Tables  2 and 3 provide a list of the other SNPs associated with ASI at a p value of <10 −5 , and Figure 1 shows the Manhattan plots for the AA and EA samples. The QQ plots of these two populations can be found in Supplementary Figures S1 and S2 . To determine population difference, the identified top SNPs in AA and EA samples were compared, which revealed a P value of 0.054 for rs17849904 in the EA population. Because of low MAF (<0.01), rs34722354 was removed from the association analysis for the AA sample.
Gene-based Analysis
To evaluate the association between ASI and all common SNPs within a gene, we performed a gene-based analysis using the VEGAS2 method. 20 The p value for 48 091 and 34 933 autosomal SNPs in the AA and EA samples were employed for the gene-based analysis. A total of 8569 and 8967 genes were tested in the AA and EA samples, respectively. Supplementary Tables S1 and S2 show the top genes with p values < 0.005 ranked by their p values from the VEGAS2 analysis for the AA and EA samples, respectively. In the AA, the only gene that remained statistically significant after Bonferroni correction was dehydrogenase/reductase 7 (DHRS7; p = 5.00 × 10 -6 ), which encodes a member of the short-chain dehydrogenases/reductase (SDR) protein family and functions as an enzyme from the SDR superfamily to contribute to the metabolism of xenobiotics. In the EA sample, the top hit was forkhead box N1 (FOXN1; p = 1.20 × 10 -5 ), which has been associated with rudimentary thymus in a previous report. 35 Furthermore, C14ORF135 was identified in both the SNP-based and the gene-based analyses. In the individual SNP-based association analysis, the most significant SNP located in PITRM1 gene, the p value for this gene was 0.02 in the gene-based association analysis.
SNP Heritability
The univariate GCTA-GREML analysis was used to estimate the proportion of variance explained by all common SNPs for the ASI phenotype in both the AA and EA samples. The estimated heritability of ASI was 0.129 (SE = 0.16) for AAs and 0.07 (SE = 0.29) for the EAs, which represents the upper limit of the amount of phenotypic variance explained by all the SNPs included in our EWAS.
Discussion
In this study, we performed a genome-wide association analysis to link about 40 000 genotyped common SNPs to the ASI for both AA and EA smokers. We obtained evidence of significant ethnicity-specific associations with ASI for non-synonymous variants rs17849904 in PITRM1 and rs34722354 in DDR2 in the AA and EA smokers, respectively. Furthermore, our gene-based association analysis indicated a putative role of DHRS7 in the AA sample, a gene that has been implicated in nicotine metabolism. 36, 37 Consistent with other reports, 38 the majority of smokers included in our samples started their regular smoking at around 18 years of age (18.3 ± 2.9 years). Compared with EA smokers (17.7 ± 3.6), AA smokers started their regular smoking at a slightly later age (18.4 ± 2.7 years). In addition, AA smokers smoke fewer cigarettes per day but are less likely to quit smoking. 39 Together, these phenotypic differences likely imply genetic differences between the AA and EA smokers. Besides, there was a negative correlation between ASI and CPD in AA (p = −0.047) and EA (p = −0.051). These results indicate that the distributions of our samples are consistent with previous epidemiological surveys. 40 So far, a number of GWAS have been conducted for various smoking behaviors, 41, 42 with several chromosomal regions repeatedly observed to be associated with ASI. Several SNPs near the HLA region on chromosome 6p21 42 and others in the nicotinic receptor candidate genes CHRNA3 on chromosome 15q25 and CHRNA1 on chromosome 2q31 41 and in an intergenic region on chromosome 2q21 42 show associations with ASI. Moreover, CYP2A6 exhibited nominally significant associations with ASI. 41 These results could be explained by the relation between CYP2A6 variation and both nicotine metabolism 43 and smoking behavior. 44 However, most of these findings were not replicated in our study, which may be a consequence of the smaller sample.
In this study, allele A of rs17849904 in PITRM1 was negatively associated with ASI, indicating a potential protective role for this locus. This implies that carriers of the minor allele would have a late smoking initiation. The PITRM1 gene encodes a 117-kDa mitochondrial matrix enzyme (also known as presequence peptidase; PreP), which contributes to digestion of mitochondrial amyloid beta (Aβ) 45 and interaction with mitochondrial targeting sequence (MTS) of proteins imported from the inner mitochondrial membrane, 46 such that mutations lead to mitochondrial dysfunction. This dysfunction is a hallmark of neurodegeneration 47 and of many psychiatric disorders such as Alzheimer's dementia (AD), 48 which is characterized by the accumulation of the Aβ peptide as plaques in the neuropil. 49 Carriers of PITRM1-R138Q missense mutations have a slowly progressive neurodegenerative phenotype. 34 Although smoking is a risk factor for Alzheimer's disease, and several important markers such as APOE have been identified, 50 the mechanism underlying the correlation between Alzheimer's disease and smoking is not fully understood. In our study, this SNP was predicted to be possibly damaging by PolyPhen, implying that rs17849904 may contribute to the functional modification of the protein.
Another association finding in the EA sample revealed a protective allele, rs34722354, in DDR2. This gene encodes a membranebound receptor tyrosine kinase that binds collagen and is involved in regulation of cell proliferation and survival. 51 Lung cancer-associated mutations have been identified in DDR2, 52 and overexpression of the gene correlates with clinicopathologic features of a poor prognosis. 53 Lung cancer is one of the most commonly observed diseases associated with tobacco smoking. Meanwhile, for rs34722354, in silico programs predict a functional modification by SIFT, which is based on the conservation of amino acid residues in sequence alignments from closely related sequences across species. The secondary structure of the protein may be destroyed by this non-synonymous mutation. Although the functional relevance of this genetic variant in smoking and smoking-related diseases such as lung cancer is still unclear, our finding suggests that rs34722354 is a plausible locus for ASI and other smoking-related phenotypes, a finding that deserves further investigation. Besides, the two loci located in the TTN gene are in high linkage disequilibrium (r 2 > 0.89) with each other. This gene encodes a large, abundant protein of striated muscle, which has been reported to be associated with a higher risk for cardiovascular death. 54 To evaluate the association between ASI and all SNPs in the gene of interest, a gene-based association test was performed using VEGAS2, which uses a list of SNP p values as inputs and then considers the underlying SNP-SNP correlation pattern employing the genotype data from the HapMap Project or other databases. 55 As reported elsewhere, 56 VEGAS2 is stable across different boundaries and remains powerful even with the inclusion of non-significant SNPs. We used the default gene boundary in VEGAS2 (± 50 kb) and focused on the top individual SNPs and previously reported genes that are related to ASI. Through this analysis, we identified a potential candidate gene, DHRS7, in the AA sample, which encodes a member of the short-chain dehydrogenases/reductase (SDR) protein family. 57 Human SDR members play important roles in various biochemical pathways, including those of intermediary metabolism and biotransformation of xenobiotics. 36 The DHRS7 gene is located on chromosome 14 and has two isoforms. Isoform 1 consists of 339 amino acids (38 kDa), and isoform 2 consists of 289 amino acids (32 kDa). Although cytochrome P450 2A6 (CYP2A6) encodes the enzyme responsible for the majority of nicotine metabolism reactions, 58 the DHRS7 product metabolizes NNK 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a secondary metabolite of nicotine in vitro. 36, 37 A previous study has demonstrated that the poor-metabolizer genotypes of CYP2A6 are associated with a later ASI. 59 Together, our gene-based analysis indicated that DHRS7 is associated with ASI, likely by changing nicotine metabolism.
Further, our gene-based analysis showed a significant association of PITRM1 with ASI, suggesting that PITRM1 represents a candidate gene for ASI, which warrants replication. Another novel candidate gene for ASI identified in this study with both individual SNP-based and gene-based analyses is C14ORF135, although there is no report on the role of this gene in smoking. Further, to investigate the contribution of common SNPs to ASI, we estimated SNP heritability using GCTA software. We found that about 12.9% of the phenotypic variance in ASI was tagged by common SNPs in the AA sample and 6.8% in the EA sample. Such findings imply that a significant number of SNPs remain to be identified for their association with ASI. Although the exact reasons are unknown, the small sample of this study may have contributed to the low detection power. Future study with larger samples is greatly needed to replicate the findings and unravel the biological mechanisms underlying these associations.
There are a few limitations of this study that should be considered. First, although our samples are rather large, they are still too small with limited power for a EWAS. More studies with significantly a large sample or meta-analysis of multiple independent samples are greatly needed to final more susceptibility variants for ASI. Second, because a limited number of SNPs within a gene were included in the exome chip used for many genes, our gene-based association analysis was not as powerful as we wanted, which might limit the number of candidate genes identified. Nevertheless, the susceptibility SNPs and genes for ASI revealed by this study are not only statistically significant but also biological meaningful, and the findings deserve to be replicated in a future study.
In sum, our individual SNP-based association analysis revealed two novel non-synonymous SNPs with one located in PITRM1 and another in DDR2 that are significantly associated with ASI in AA and EA smokers, respectively. Furthermore, our gene-based analysis revealed that DHRS7 is a novel candidate gene for ASI. Given the documented biological roles of these genes, more replications with a large sample and molecular studies are needed in the future.
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